Literature DB >> 17394036

Cardiac sarcoidosis responding to monotherapy with infliximab.

Imad Uthman1, Zahi Touma, Maurice Khoury.   

Abstract

Cardiac involvement is a rare and potentially life-threatening complication of sarcoidosis. We report the case of a young previously healthy woman who presented with complete atrioventricular heart block. Further evaluation revealed non-caseating granulomas in the hilar and mediastinal regions. A pacemaker was inserted, and she was treated with four doses of infliximab after she refused treatment with steroids. Rapid resolution of the pulmonary lymph nodes was documented and repeated interrogations of the pacemaker 1 year after her last infliximab infusion documented that she was in sinus rhythm. Infliximab may be considered as an alternative first-line therapy in sarcoidosis with serious organ involvement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394036     DOI: 10.1007/s10067-007-0614-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Infliximab for refractory sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2001-03       Impact factor: 0.670

2.  Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art.

Authors:  Om P Sharma
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

3.  Refractory neurosarcoidosis: a dramatic response to infliximab.

Authors:  John D Carter; Joanne Valeriano; Frank B Vasey; Bryan Bognar
Journal:  Am J Med       Date:  2004-08-15       Impact factor: 4.965

4.  Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.

Authors:  A M Yee; M B Pochapin
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

Review 5.  Cardiac sarcoidosis--an occult cause of sudden death: a case report and literature review.

Authors:  J P Veinot; B Johnston
Journal:  J Forensic Sci       Date:  1998-05       Impact factor: 1.832

6.  TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.

Authors:  Daniel R Roach; Andrew G D Bean; Caroline Demangel; Malcolm P France; Helen Briscoe; Warwick J Britton
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

8.  Racial difference in cardiac sarcoidosis incidence observed at autopsy.

Authors:  K Iwai; M Sekiguti; Y Hosoda; R A DeRemee; H D Tazelaar; O P Sharma; A Maheshwari; T I Noguchi
Journal:  Sarcoidosis       Date:  1994-03

9.  Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.

Authors:  Kai U Ulbricht; Matthias Stoll; Janine Bierwirth; Torsten Witte; Reinhold E Schmidt
Journal:  Arthritis Rheum       Date:  2003-12

10.  Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.

Authors:  K J Silverman; G M Hutchins; B H Bulkley
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

View more
  20 in total

1.  The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.

Authors:  Khaled M Musallam; Thurayya Arayssi; Ali T Taher; Nadim Kanj; Imad Uthman
Journal:  Rheumatol Int       Date:  2008-12-04       Impact factor: 2.631

2.  A Diagnostic and Therapeutic Approach to Arrhythmias in Cardiac Sarcoidosis.

Authors:  Brian A Houston; Carolyn Park; Monica Mukherjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

3.  Ventricular tachycardia as the first manifestation of cardiac sarcoidosis.

Authors:  Felix Mehrhof; Martin Stockburger; Hartwig Schuette; Wilhelm Haverkamp; Rainer Dietz
Journal:  BMJ Case Rep       Date:  2009-04-28

Review 4.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

Review 5.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Cardiac sarcoidosis: diagnosis and management.

Authors:  Michelle Bussinguer; Alfred Danielian; Om P Sharma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

Review 7.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

8.  TNF-alpha inhibition for the treatment of cardiac sarcoidosis.

Authors:  Matthew C Baker; Khushboo Sheth; Ronald Witteles; Mark C Genovese; Stanford Shoor; Julia F Simard
Journal:  Semin Arthritis Rheum       Date:  2019-11-15       Impact factor: 5.532

9.  Case Report: TNFα Antagonists Are an Effective Therapy in Cardiac Sarcoidosis.

Authors:  Julien Stievenart; Guillaume Le Guenno; Marc Ruivard; Virginie Rieu; Marc André; Vincent Grobost
Journal:  Front Cardiovasc Med       Date:  2021-06-11

10.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.